Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Sandesh Mahatme currently holds 13,000 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sandesh Mahatme has been a net seller of CRSP stock. They have purchased $155.5K and sold $50.9M worth of shares.
Sandesh Mahatme's most recent insider trade was on Jun 5, 2026, when they sold 13,000 shares at $0.00 per share.
Sandesh Mahatme serves as Executive at CRISPR Therapeutics AG (CRSP). They have executed 72 insider transactions totaling $51.0M over their tenure at the company.
Sandesh Mahatme holds the position of Executive at CRISPR Therapeutics AG, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 13 years and currently hold a stake valued at $0.
Sandesh Mahatme has shown a selling trading pattern, with $155.5K in total purchases and $50.9M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Sandesh Mahatme was on Dec 13, 2019, when they sold $15.7M worth of SRPT shares. This transaction involved 125,000 shares at $125.50 per share.
Sandesh Mahatme currently owns 13,000 shares of CRISPR Therapeutics AG (CRSP), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Sandesh Mahatme's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Sandesh Mahatme has 72 Form 4 filings on record as an insider at CRISPR Therapeutics AG.
Set alerts for Sandesh Mahatme and 40,000+ other insiders.